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Purpose: Exogenous administration of sphingosine-1-phosphate (S1P) alone, or as part of high density
lipoprotein, protects againstmyocardial infarction. S1P-induced cardioprotection targets the inhibition
of the mitochondrial permeability transition pore via mechanisms that remain unclear.
In the cell, the endogenous production of S1P from sphingosine is dependent on the activation of
sphingosine kinases (SphK) 1 and 2. These two kinases play a role in cardioprotection against
ischemia-reperfusion (IR) injury. Therefore, we hypothesised that the cardioprotective effect of ex-
ogenous S1P requires the activation of endogenous S1P via SphK.
Methods: Isolated cardiomyocytes from adult wildtype mice were exposed to 2 hours of simulated
ischemia (SI) in the presence of S1P (10nM) with/without N,N-dimethylsphingosine (DMS, a SphK1
and 2 inhibitor, 10mM) or SKI (a specific SphK1 inhibitor, 15mM). Cell viability was assessed using
trypan blue staining and normalised to the normoxic control.
Isolated perfused hearts from adult wildtype mice were exposed to 35 minutes of global ischemia fol-
lowedby45minutesof reperfusion (IR) in thepresenceof S1P (10nM)with/without SKI (10mM). Infarct
size (IS) was assessed using tripheyltetrazolium chloride staining and SphK1 activity using a specific bio-
chemical fluorescence based assay kit. Both parameters were normalised to the IR control.
Results: In isolated cardiomyocytes, viability under normoxic conditions was 76+1%. SI reduced via-
bility to 52+1% (p, 0.001 vs. normoxia). Pre-treatment with S1P restored the viability to 75+1%
(p,0.001 vs. SI). The beneficial effect of S1P was partially inhibited in the presence of DMS
(67+4%) (ns vs. S1P) and totally abrogated with SKI pre-treatment (54+2%).
Similarly, pre-treatmentwith S1P in isolatedhearts reduced IS following IR from50+1% (IR control) to
31+2% (S1P) (p,0.001 vs. control). Pre-treatment with SKI abrogated the cardioprotective effect of
S1P (56+8%) (p,0.05 vs. S1P) as well as the S1P-induced increase in SphK1 activity (from S1P:
196+79 arbitrary units (AU) to SKI+S1P: 53+27 AU, p,0.05 vs. S1P).
Conclusions:Our data, performed in both isolated cardiomyocytes and isolated hearts subjected to
an ischemia/reperfusion insult, strongly suggest that exogenous sphingosine-1-phosphate-induced car-
dioprotection is dependent on the activation of endogenous sphingosine-1-phosphate via sphingosine
kinase 1.
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